Skip to main content
Premium Trial:

Request an Annual Quote

Caliper's $25M Loan Agreement Amended

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences said that it has entered into a third amendment and restated loan and security agreement with Silicon Valley Bank extending the maturity date of a credit facility and reducing the applicable interest rate and facility fees to be paid by Caliper.

The new amendment, disclosed in a document filed with the US Securities and Exchange Commission this week, pertains to an agreement with SVB, under which Caliper can borrow up to $25 million in the form of a revolving loan.

Under the terms of the third amendment, the maturity date on the credit facility has been extended to April 1, 2013. Also, the interest rate and facility fees to be paid by Caliper have been reduced, while the advance rate against Caliper's cash held at SVB for determining how much Caliper can borrow under the credit facility has been increased.

Caliper had previously said the cash from the credit facility will be used for ongoing operations and working capital needs.

The firm recently paid around $20 million, of which $7.9 million was in cash, to acquire Cambridge Research & Instrumentation.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.